Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > 90, 180, 360.... CR% the same.

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Nov 01, 2021 9:57pm

317 Views

Post# 34075658

RE:RE:90, 180, 360.... CR% the same.

My apologies - I said November 5 expiry -- it should have said November 10 expiry.

Pandora wrote: 37.5 cent warrants expire November 5. Will they allow them to expire or will they extend them? That should be one news release for the beginning of the week.

wildbird1 wrote: CR%(Complete Response)
According to TLT, comparing the 90 and 180 day data, demonstrate that once a patient has obtained CR(complete response) or PR(partial response), the duration of the response remain approxmimately the same.

The above indicate that if the 90 day CR is approximately the same at 180,360.... day, it will be very interesting to see if the FDA take the above into account and give Breakthrought Designation faster approval.

Shares out.
Right now TLT has 204 million shares out, and 57 million warrants(0.35$) from the last prospectus August 22,2019.
If exercised these warrants will bring the total to 261 million shares out, and $20 million more in the Bank for TLT.
261 million shares out is still a puny little number of shares out for a company on the brink of finding a solution not only for Bladder Cancer but for many cancer.

Can't wait for the next 2 Quaterly Newsletter and the CR% at 90 and 180 day of all the optimized patients. The 180 day CR% will open a lot of eyes (including the FDA).

According to peoples on this board that have a better understanding of the Quaterly Newsletter numbers the CR% could easily be over 70%.
70% CR(or more) is huge for a treatment that treat only " End Of The Line Patients".